ReviewFrontiers in microbiology2016
Inflammation-inducing Factors of Mycoplasma pneumoniae.
Review in Frontiers in microbiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
69 citing papers in PubMed, 109 citations in OpenAlex.
- Immunopathogenesis and Cytokine Pathways in Reactive Infectious Mucocutaneous Eruption (RIME) in Pediatric Population: Infectious Triggers and Molecular Insights.Clinical reviews in allergy & immunology · 2026Review
- USP17L2 Regulates SphK1 Ubiquitination and Stability during Autophagy and Pyroptosis in Mycoplasma Pneumoniae Pneumonia.Applied biochemistry and biotechnology · 2026Article
- Immune Dysregulation and Cytokine Profiling in AcuteMicroorganisms · 2026Article
- Population-specific dysbiosis of the salivary microbiota in Saudi adults with periodontitis.BMC microbiology · 2026Article
- Levels of Toll-Like Receptor 2, Myeloid Differentiation Primary Response 88 and Mucin 5AC, Oligomeric Mucus/Gel-Forming in Bronchoalveolar Lavage Fluid for Predicting SevereInfection and drug resistance · 2026Article
- Thrombotic thrombocytopenic purpura and macrophage activation syndrome secondary to Sjögren's syndrome: a case report.Frontiers in immunology · 2026Article
- Clinical Prediction of Necrotizing Pneumonia in Children With Mycoplasma pneumoniae: A Model Based on Early Response to Therapy.Canadian respiratory journal · 2026Article
- Clinical characteristics and predictor analysis of pediatric Mycoplasma pneumoniae pneumonia with small segment molded sputum plugs: a retrospective study.Italian journal of pediatrics · 2025Article
- Unraveling the role of distinct cytoskeletal motility structures in Mycoplasma pneumoniae relatives.BMC microbiology · 2025Review
- Correlation analysis between clinical characteristics of adult patients with Mycoplasma pneumoniae pneumonia and 23S rRNA A2063 gene in alveolar lavage fluid.BMC pulmonary medicine · 2025Article
- Differential Immunological Responses of Adult Domestic and Bighorn Sheep to Inoculation withMicroorganisms · 2024Article
- Review
- Heterologous protein exposure and secretion optimization in Mycoplasma pneumoniae.Microbial cell factories · 2024Article
- Atypical pneumonia (Review).Experimental and therapeutic medicine · 2024Review
- Baicalin and lung diseases.Naunyn-Schmiedeberg's archives of pharmacology · 2024Review
- Aerobic glycolysis of bronchial epithelial cells rewiresInfection and immunity · 2024Article
- Insights into the defensive roles of lncRNAs duringFrontiers in microbiology · 2024Review
- Clinical characteristics and risk factors forFrontiers in pediatrics · 2024Article
- Identification ofFrontiers in microbiology · 2024Article
- Understanding the molecular regulatory mechanisms of autophagy in lung disease pathogenesis.Frontiers in immunology · 2024Review
9 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mycoplasma pneumoniae, which causes mycoplasmal pneumonia in human, mainly causes pneumonia in children, although it occasionally causes disease in infants and geriatrics. Some pathogenic factors produced by M. pneumoniae, such as hydrogen peroxide and Community-Acquired Respiratory Distress Syndrome (CARDS) toxin have been well studied. However, these factors alone cannot explain this predilection. The low incidence rate of mycoplasmal pneumonia in infants and geriatrics implies that the strong inflammatory responses induced by M. pneumoniae coordinate with the pathogenic factors to induce pneumonia. However, M. pneumoniae lacks a cell wall and does not possess an inflammation-inducing endotoxin, such as lipopolysaccharide (LPS). In M. pneumoniae, lipoproteins were identified as an inflammation-inducing factor. Lipoproteins induce inflammatory responses through Toll-like receptors (TLR) 2. Because Mycoplasma species lack a cell wall and lipoproteins anchored in the membrane are exposed, lipoproteins and TLR2 have been thought to be important for the pathogenesis of M. pneumoniae. However, recent reports suggest that M. pneumoniae also induces inflammatory responses also in a TLR2-independent manner. TLR4 and autophagy are involved in this TLR2-independent inflammation. In addition, the CARDS toxin or M. pneumoniae cytadherence induces inflammatory responses through an intracellular receptor protein complex called the inflammasome. In this review, the inflammation-inducing factors of M. pneumoniae are summarized.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.